Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4416951 | 0.88 | POLB (0.47) | SMN1; SMN2MAPTALDH1A1POLBMAPK1 | |
| SCHEMBL4417061 | 0.86 | ALDH1A1 (0.49) | SMN1; SMN2MAPTALDH1A1POLBMAPK1 | |
| SCHEMBL4414941 | 0.85 | POLB (0.44) | SMN1; SMN2MAPTALDH1A1POLBMAPK1 | |
| SCHEMBL6953752 | 0.81 | CYP2C9 (0.40) | SMN1; SMN2MAPTALDH1A1POLBMAPK1 | |
| SCHEMBL4421386 | 0.81 | POLB (0.36) | MAPTALDH1A1POLBLMNA | |
| SCHEMBL4414781 | 0.75 | MAPT (0.38) | MAPTALDH1A1POLBCYP1A2CYP3A4 | |
| SCHEMBL6949240 | 0.75 | TSHR (0.46) | SMN1; SMN2MAPTALDH1A1POLBMAPK1 | |
| SCHEMBL4417030 | 0.74 | POLB (0.51) | SMN1; SMN2MAPTALDH1A1POLBMAPK1 | |
| SCHEMBL4412461 | 0.74 | MAPT (0.46) | SMN1; SMN2MAPTALDH1A1POLBMAPK1 | |
| SCHEMBL6949181 | 0.74 | TSHR (0.43) | SMN1; SMN2MAPTALDH1A1POLBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1397351-B1 | PYRIMIDINE, TRIAZINE AND PYRAZINE DERIVATIVES AS GLUTAMATE RECEPTORS | HOFFMANN LA ROCHE (CH) | 2009-11-11 | — | — | EP | claimed |
| CN-1245391-C | Pyrimidine, Triazine and pyrazine derivatives as glutamate receptors | HOFFMANN LA ROCHE (CH) | 2006-03-15 | — | — | CN | claimed |
| CN-1512988-A | Pyrimidine, Triazine and pyrazine derivatives as glutamate receptors | - | 2004-07-14 | — | — | CN | claimed |
| EP-1397351-A1 | PYRIMIDINE, TRIAZINE AND PYRAZINE DERIVATIVES AS GLUTAMATE RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-17 | — | — | EP | claimed |
| US-6673795-B2 | SUCH AS 6-(4-(4-FLUORO-PHENYL)-PIPERAZIN-1-YL)-2-METHYL-5-NITRO-3-(2,2,2-TRIFLUORO -ETHYL)-3H-PYRIMIDIN-4-ONE, WHICH ARE METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS USEFUL IN TREATING PSYCHOLOGICAL DISORDERS | HOFFMANN-LA ROCHE INC. | 2004-01-06 | — | — | US | claimed |
| US-20030060466-A1 | Pyrimidine, pyrazine and triazine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2003-03-27 | — | — | US | claimed |
| WO-2002098864-A1 | PYRIMIDINE, TRIAZINE AND PYRAZINE DERIVATIVES AS GLUTAMATE RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-12-12 | — | — | WO | claimed |
| EP-1397351-B1 | PYRIMIDINE, TRIAZINE AND PYRAZINE DERIVATIVES AS GLUTAMATE RECEPTORS | HOFFMANN LA ROCHE (CH) | 2009-11-11 | — | — | EP | disclosed |
| CN-1245391-C | Pyrimidine, Triazine and pyrazine derivatives as glutamate receptors | HOFFMANN LA ROCHE (CH) | 2006-03-15 | — | — | CN | disclosed |
| CN-1512988-A | Pyrimidine, Triazine and pyrazine derivatives as glutamate receptors | - | 2004-07-14 | — | — | CN | disclosed |
| EP-1397351-A1 | PYRIMIDINE, TRIAZINE AND PYRAZINE DERIVATIVES AS GLUTAMATE RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-17 | — | — | EP | disclosed |
| US-6673795-B2 | SUCH AS 6-(4-(4-FLUORO-PHENYL)-PIPERAZIN-1-YL)-2-METHYL-5-NITRO-3-(2,2,2-TRIFLUORO -ETHYL)-3H-PYRIMIDIN-4-ONE, WHICH ARE METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS USEFUL IN TREATING PSYCHOLOGICAL DISORDERS | HOFFMANN-LA ROCHE INC. | 2004-01-06 | — | — | US | disclosed |
| US-20030060466-A1 | Pyrimidine, pyrazine and triazine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2003-03-27 | — | — | US | disclosed |
| WO-2002098864-A1 | PYRIMIDINE, TRIAZINE AND PYRAZINE DERIVATIVES AS GLUTAMATE RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060466-A1 | Pyrimidine, pyrazine and triazine derivatives | P2RX5, IL5, P2RX2 | SMN1; SMN2 336/4885MAPT 1578/4885ALDH1A1 2009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.